RMI2 Antibody / BLAP18 / RecQ-mediated genome instability protein 2

Overview

RMI2 Antibody / BLAP18 / RecQ-mediated genome instability protein 2 is an antibody targeting BLAP18, raised in Rabbit for protein detection and localization studies where these specifications are required.

Key elements and design rationale

• Target: BLAP18.
• Antibody identity: Polyclonal (rabbit origin); Rabbit IgG.
• Conjugate/label: Unconjugated (affects detection chemistry and multiplex compatibility).
• Format: Antigen affinity purified.
• Species reactivity: Human, Mouse, Rat.
• Listed applications: WB, ELISA (refer to on-page specifications for application-specific guidance).

Biological background

RMI2 is a component of the BLM (RECQL3) complex, which plays a role in homologous recombination-dependent DNA repair and is essential for genome stability. This gene is mapped to 16p13.13. RMI1 and RMI2 were present in approximately stoichiometric amounts with other BLM complex components, including topoisomerase-3-alpha (TOP3A), RPA (see RPA1), and BLAP250. RMI2 also associated with RMI1 and TOP3A in a second complex. RMI1 and RMI2 interacted directly, and both were essential for stability of the BLM complex. Depletion of either RMI1 or RMI2 depleted the other protein by 80 to 90%. Chicken DT40 cells depleted of Rmi2 displayed elevated sister chromatid exchange, but other functions of the BLM complex appeared intact. Mutation analysis revealed that interaction between human RMI2 and BLM was essential for suppression of sister chromatid exchange.

Research relevance and current trends

• Comparative expression profiling across cell types, tissues, or perturbations (e.g., drug treatment, genetic editing, or differentiation).
• Subcellular localization and trafficking studies, including co-localization with pathway markers in microscopy-based assays.
• Integration of protein-level measurements with transcriptomics or proteomics to relate abundance to regulation and phenotype.

Common research applications

• Western blotting: researchers commonly compare relative signal levels across conditions and use appropriate negative/positive controls for interpretation.
• ELISA: researchers commonly compare relative signal levels across conditions and use appropriate negative/positive controls for interpretation.

Interpretation should account for antibody-dependent factors such as epitope accessibility, isoforms, and sample preparation differences across workflows.

Notes for experimental interpretation

• Isoforms and PTMs: many targets have multiple isoforms and post-translational modifications that can shift apparent signal or localization; interpret bands/signals accordingly.
• Epitope context: binding can depend on protein conformation and sample processing; region information in the title/immunogen can help anticipate what may be detected.
• Species differences: predicted or validated reactivity may vary by ortholog sequence and sample context; confirm in your model system.
• Control concepts: include negative controls (no-primary/isotype), and where possible genetic controls (KO/KD) or independent antibodies to strengthen conclusions.

Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.